查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806348

抗癌药物市场按药物类型、给药途径、治疗类型、癌症类型、最终用户和分销管道划分－2025-2030 年全球预测

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年抗癌药物市场规模将达1,571亿美元，2025年成长至1,720.6亿美元，复合年增长率为9.81%，2030年将达2,754.8亿美元。

主要市场统计数据
基准年2024年 1571亿美元
预计2025年 1720.6亿美元
预测年份 2030 2754.8亿美元
复合年增长率（%） 9.81%

透过揭示根本驱动因素、新兴创新和战略产业要求，为癌症药物分析奠定基础

抗癌药物研发的复杂性需要一篇有理有据的导言，概述塑造癌症治疗领域的基本力量。细緻入微地理解过去的突破，对于解读化疗、标靶治疗和免疫调节剂领域的持续进展至关重要。本文将借镜历史里程碑，阐明增加的研究资金、拓展的监管途径以及以病人为中心的医疗模式如何影响当代的优先事项。

引领由技术突破和不断发展的患者照护模式推动的肿瘤药物开发的重大转变

过去十年，在免疫肿瘤学和分子标靶治疗领域取得突破的推动下，一场变革性变革重新定义了肿瘤治疗方法模式。查核点抑制剂重塑了多种癌症的治疗流程方案，并促使阈值治疗和组合方案的重新设计。同时，嵌合体抗原受体T细胞疗法已从实验性治疗方法迈向商业性化，预示着个人化免疫疗法新时代的到来。

评估美国新征收的关税对抗癌药物供应链、定价动态和国际竞争平衡的影响

美国将于2025年初实施新的关税，这将为肿瘤学价值链上的相关人员带来巨大阻力。采购和分销合作伙伴面临着从全球供应商采购关键活性药物原料药的成本上涨，这促使他们重新评估其生产布局。近几个月来，一些公司采取了应对措施，包括多元化供应商、投资近岸外包以及重新谈判长期合同，以减轻关税的影响并确保药品供应的不间断。

揭示药物类别、给药途径、治疗方式、癌症适应症、最终用户概况和分销网络的关键细分洞察

透过分析每个药物类别及其各自的子类别，可以清楚地洞察癌症治疗市场。化疗仍然是主要的治疗方法，烷化剂、抗代谢药物和抗肿瘤抗生素在根除肿瘤方面表现出不同的疗效和安全性。除了传统的细胞毒性疗法外，免疫疗法还引入了查核点抑制剂和CAR-T疗法，每种疗法都需要专门的给药方案和患者监测。

探索美洲、欧洲、中东和非洲以及亚太地区的区域动态和有效的市场驱动力

区域环境透过医疗基础设施、法规环境和报销机制的差异，影响抗癌药物的部署和采用。在美洲，成熟的专科药房网络与领先的研究中心相辅相成，促进了先进疗法的积极应用。北美的卓越中心正在与付款人合作，制定创新的报销方案，以降低前期成本并将疗效与价值挂钩。

揭示塑造癌症治疗生态系统的主要企业的策略性倡议、合作和创新组合

主要产业参与者正在重新调整其策略重点，以适应不断发展的癌症治疗格局。领先的创新企业正在透过投资早期发现计画和后期临床试验并多元化其投资组合来拓展广泛的免疫肿瘤学产品线。生技公司与大型製药企业之间的发展正在加速，这使得能够达成再授权和共同开发契约授权合约，从而分散风险并利用互补的专业知识。

为行业领导者提供策略要点和实用建议，以利用新的商业机会并应对日益复杂的肿瘤市场

产业领导者应优先考虑整合研发框架，将发现、转化研究和临床应用连接起来，以加速从概念到商业化的进程。建立跨职能的卓越中心，整合药物化学、生物标记分析和监管专业知识，可以简化决策流程并缩短开发时间。同时，与诊断供应商建立策略联盟，可以共同开发伴随检测，从而增强个人化治疗通讯协定。

全面阐述支持肿瘤药物研究的严格调查方法、资料收集通讯协定和分析框架

本研究采用多维度的方法，结合深入的二手资料研究、一手专家访谈和严格的资料三角检验，确保分析的稳健性。对同行评审期刊、监管指南和临床试验註册库的广泛文献综述，为理解治疗进展提供了基础。同时，本研究也分析了专有资料库和产业出版刊物，以了解竞争和专利格局。

整合核心发现、对产业的影响、持续推进抗癌药物创新的观点

综合来看，主要研究结果表明，免疫肿瘤学、精准医疗工具以及数位健康融合领域的突破正在重新定义癌症治疗的范式。新贸易政策的累积影响凸显了建构韧性供应链和创新报销策略的必要性，以保障患者获得治疗并实现商业性可行性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 将CAR-T细胞疗法拓展至固态肿瘤早期治疗
  • 以生物标记为重点的监管核准正在推动肿瘤无关治疗方法的增长
  • 透过整合人工智慧驱动的诊断平台优化个人化癌症药物选择
  • 增加对口服溶瘤药物的投资，用于晚期癌症患者的慢性治疗
  • 免疫疗法与标靶小分子结合的联合治疗激增
  • 利用液态生物检体引导的治疗监测加速精准肿瘤学
  • 具有新型细胞毒性有效载荷的新一代抗体药物偶联物的出现
  • 生技公司与大型製药公司进行策略合作，快速开发肿瘤学产品线
  • 促进孤儿药途径中孤儿药开发的监管奖励
  • 采用真实世界证据支持上市后监测和附加檔扩展

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：抗癌药物市场（依药物类型）

  • 化疗
    • 烷化剂
    • 抗代谢药
    • 抗肿瘤抗生素
  • 荷尔蒙疗法
  • 免疫疗法
  • 标靶治疗
    • 诱导凋亡药物
    • 单株抗体
    • 蛋白酪氨酸激酶抑制剂（TKI）

第九章：抗癌药物市场（依给药途径）

  • 肌肉注射
  • 静脉
  • 口服
  • 皮下

第 10 章：抗癌药物市场（依治疗类型）

  • 联合治疗
  • 单药治疗

第十一章 抗癌药物市场（以癌症类型）

  • 乳癌
  • 大肠直肠癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 摄护腺癌

第 12 章：抗癌药物市场（以最终用户划分）

  • 门诊治疗中心
  • 家庭医疗保健
  • 医院和诊所

第 13 章：抗癌药物市场（依分销管道）

  • 医院药房
  • 零售药局

第 14 章：美洲抗癌药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第十五章欧洲、中东和非洲抗癌药物市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第十六章：亚太地区抗癌药物市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • Amgen Inc.
    • Astellas Pharma Inc
    • AstraZeneca PLC
    • Bayer AG
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Fresenius Kabi AG
    • Getwell Oncology Pvt Ltd
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Kite Pharma, Inc by Gilead Company
    • Medivir AB
    • Merck & Co., Inc.
    • Nammi Therapeutics, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
    • Takeda Pharmaceutical Company Limited

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 157.10 billion in 2024 and is projected to grow to USD 172.06 billion in 2025, with a CAGR of 9.81%, reaching USD 275.48 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 157.10 billion
Estimated Year [2025] USD 172.06 billion
Forecast Year [2030] USD 275.48 billion
CAGR (%) 9.81%

Establishing the Foundation of Cancer Drug Analysis by Highlighting Fundamental Drivers, Emerging Innovations, and Strategic Industry Imperatives

The complexity of cancer drug development demands a well-grounded introduction that outlines the fundamental forces shaping the oncology therapeutic sphere. A nuanced understanding of past breakthroughs provides essential context for interpreting ongoing advancements in chemotherapies, targeted approaches, and immunomodulatory agents. Building from historical milestones, this introduction illuminates how intensified research funding, expanded regulatory pathways, and patient-centric care models converge to influence contemporary priorities.

Moreover, rapid technological evolution in molecular diagnostics and biomarker discovery has created new opportunities for precision oncology, driving collaboration among academic institutions, biotech startups, and established pharmaceutical developers. In this light, the introduction establishes a framework for how shifting regulatory paradigms-such as accelerated approval programs and adaptive licensing-facilitate the entry of innovative compounds while ensuring patient safety.

By setting the stage with key research enablers, stakeholder motivations, and cross-sector partnerships, this section underscores the dynamic environment in which oncology stakeholders operate. It paves the way for subsequent analysis of disruptive trends and market-shaping events, providing readers with a cohesive starting point to appreciate the deeper insights that follow.

Navigating the Pivotal Transformations in Oncology Drug Development Driven by Technological Breakthroughs and Evolving Patient Care Paradigms

Over the past decade, transformative shifts have redefined the oncology therapeutics landscape, driven by breakthroughs in immuno-oncology and molecularly targeted treatments. Checkpoint inhibitors have reshaped therapeutic algorithms across multiple cancer types, prompting redesigns of standard of care and combination regimens. Simultaneously, chimeric antigen receptor T cell therapies have crossed thresholds from experimental modalities to commercial realities, heralding a new era of personalized immunotherapy.

In parallel, the convergence of big data analytics and precision medicine tools has accelerated the identification of patient subpopulations most likely to benefit from specific interventions. This evolution has compelled industry leaders to integrate companion diagnostics into clinical development plans, fostering collaborative models between diagnostic and therapeutic stakeholders. Moreover, digital health platforms now support remote monitoring and real-time outcome tracking, enhancing trial efficiency and enabling adaptive trial designs that reduce development timelines.

As regulatory bodies refine frameworks for advanced therapies, the industry adapts by forging strategic alliances, expanding manufacturing capabilities, and integrating artificial intelligence for compound discovery. These advances underscore an ongoing paradigm shift that elevates efficacy, safety, and patient-centricity at the heart of oncology R&D.

Assessing the Ramifications of Newly Implemented United States Tariffs on Cancer Drug Supply Chains, Pricing Dynamics, and Global Competitive Equilibrium

The implementation of new United States tariffs in early 2025 has introduced significant headwinds for stakeholders across the cancer drug value chain. Procurement and distribution partners are facing increased costs for critical active pharmaceutical ingredients sourced from global suppliers, prompting a reassessment of manufacturing footprints. In recent months, several organizations have responded by diversifying supplier bases, investing in nearshoring initiatives, and renegotiating long-term contracts to mitigate tariff exposure and secure uninterrupted drug availability.

Furthermore, heightened import duties on specialized components have compelled pharmaceutical companies to adjust pricing frameworks, which in turn places pressure on reimbursement dialogues with payers. Payer panels and health technology assessment bodies are closely monitoring these cost adjustments, leading some manufacturers to pursue risk-sharing agreements and performance-based contracts to sustain market access.

Transitioning beyond immediate cost considerations, industry participants are also reevaluating supply chain resilience by integrating advanced analytics for demand forecasting and inventory management. These strategic shifts underscore the multifaceted impact of tariff introductions, demonstrating how regulatory trade actions can cascade through production, pricing, and patient access, ultimately reshaping competitive dynamics in oncology drug markets.

Unraveling Critical Segmentation Insights across Drug Classes, Administration Pathways, Therapy Modalities, Cancer Indications, End User Profiles, and Distribution Networks

Insight into the oncology drug market emerges clearly when dissecting therapeutic classes alongside their respective subcategories. Chemotherapy remains a cornerstone modality, with alkylating agents, antimetabolites, and antitumor antibiotics demonstrating differentiated efficacy profiles and safety considerations in tumor eradication. Beyond traditional cytotoxics, the immunotherapy cohort has introduced checkpoint inhibitors and CAR-T treatments, each requiring specialized administration protocols and patient monitoring.

Administration routes further refine market understanding by highlighting patient convenience and adherence factors. Intravenous infusions dominate hospital settings, whereas oral formulations offer greater flexibility for outpatient management and home healthcare delivery. Intramuscular and subcutaneous injections occupy niche roles in maintenance therapies and prophylactic regimens, reflecting a balance between therapeutic intent and patient experience.

Therapy type segmentation, distinguishing combination regimens from monotherapy approaches, reveals evolving clinical strategies aimed at overcoming resistance and enhancing synergistic effects. Cancer type delineation uncovers unique demand patterns across breast, colorectal, liver, lung, pancreatic, and prostate cancer cohorts, each presenting distinct molecular targets and treatment pathways.

End user segmentation clarifies distribution of care delivery, from hospitals and clinics as centralized hubs to ambulatory care centers and home healthcare solutions that prioritize patient comfort. Distribution channel analysis underscores the roles of hospital pharmacies in inpatient settings and retail pharmacies in broadening access for maintenance therapies.

Exploring Regional Dynamics and Differentiated Market Drivers across the Americas, Europe Middle East and Africa, and the Asia Pacific Oncology Landscapes

Regional landscapes shape the deployment and adoption of cancer therapeutics through variations in healthcare infrastructure, regulatory environments, and reimbursement mechanisms. In the Americas, well-established specialty pharmacy networks complement leading research centers, driving robust uptake of advanced therapies. North American centers of excellence collaborate with payers to structure innovative reimbursement schemes that mitigate upfront costs and link outcomes to value.

Moving eastward, the Europe, Middle East, and Africa region presents a tapestry of regulatory frameworks. While Western European nations lean on centralized approval pathways and stringent health technology assessments, Middle Eastern markets are investing heavily in oncology infrastructure and forging public-private partnerships to expand access. African markets continue to build foundational oncology programs, with an increasing focus on affordable generics and biosimilars to bridge treatment gaps.

Across the Asia-Pacific domain, diverse economies drive heterogenous demand patterns. Advanced markets such as Japan and Australia leverage strong R&D ecosystems and integrated care models, while emerging economies prioritize capacity building in oncology centers and localization of manufacturing. Regional harmonization efforts aim to streamline regulatory submissions, accelerating the entry of novel agents into clinical practice and supporting patient-centric care models.

Illuminating Strategic Moves, Collaborative Endeavors, and Innovation Portfolios of Leading Entities Shaping the Cancer Therapeutics Ecosystem

Key industry participants have recalibrated their strategic priorities to align with the evolving oncology therapeutic environment. Leading innovators have pursued expansive immuno-oncology pipelines, investing in both early-stage discovery programs and late-stage clinical trials to diversify their portfolios. Collaboration between biotechs and major pharmaceutical firms has accelerated, enabling sublicensing deals and co-development agreements that distribute risk and leverage complementary expertise.

Manufacturers with robust biologics infrastructure are expanding capacity for cell and gene therapies, preempting anticipated manufacturing bottlenecks. Simultaneously, the emergence of digital health partnerships has allowed select companies to integrate real-world evidence collection into their launch strategies, enhancing post-market value propositions. Players with global regulatory experience are optimizing dossier submissions to navigate complex approval pathways, particularly in regions adopting novel regulatory paradigms.

Smaller specialized firms are capitalizing on niche targets, forging alliances to secure co-marketing opportunities and expand trial networks. Across the competitive landscape, agility and scientific differentiation have emerged as critical differentiators, enabling companies to position their assets effectively against established standards of care and pipeline entrants.

Strategic Imperatives and Pragmatic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Oncology Market Complexities

Industry leaders should prioritize integrated R&D frameworks that bridge discovery, translational research, and clinical application to accelerate the path from concept to commercialization. Establishing cross-functional centers of excellence that coalesce medicinal chemistry, biomarker analytics, and regulatory expertise can streamline decision making and reduce development timelines. In parallel, forging strategic alliances with diagnostics providers will enable the co-development of companion assays that bolster personalized treatment protocols.

To mitigate supply chain vulnerabilities exposed by recent trade policy shifts, organizations must diversify sourcing strategies and invest in advanced supply planning platforms. Scenario modeling and digital twins for logistics networks can empower procurement teams to anticipate disruptions and maintain consistent access to high-value active pharmaceutical ingredients. Moreover, engaging payers early to define outcome-based reimbursement frameworks will align commercial strategies with therapeutic value and ensure sustained market access.

Finally, embedding patient-centricity through digital support services and telehealth integration can enhance adherence, real-world data capture, and long-term outcomes tracking. By adopting these recommendations, industry players can fortify their competitive positioning and lead in delivering next-generation oncology treatments.

Comprehensive Elucidation of Rigorous Research Methodologies, Data Collection Protocols, and Analytical Frameworks Underpinning the Oncology Drug Study

This research employs a multifaceted methodology that integrates exhaustive secondary research, primary expert interviews, and rigorous data triangulation to ensure analytical robustness. Extensive literature reviews of peer-reviewed journals, regulatory guidelines, and clinical trial registries provided a foundational understanding of therapeutic advancements. Concurrently, proprietary databases and industry publications were analyzed to map competitive activity and patent landscapes.

Primary insights were garnered through structured interviews with senior executives, clinical investigators, and reimbursement specialists, yielding firsthand perspectives on pipeline strategies, market access barriers, and patient needs. Quantitative and qualitative findings were cross-validated through triangulation techniques, ensuring consistency across data sources and minimizing bias.

Furthermore, the study incorporated scenario analyses to examine the impact of policy shifts, such as tariff implementations, on production and distribution dynamics. Ethical adherence to data privacy and confidentiality standards was maintained throughout. The resulting framework synthesizes complex inputs into a coherent narrative, furnishing stakeholders with actionable intelligence underpinned by transparent methodologies.

Synthesis of Core Findings, Industry Implications, and Forward-Looking Perspectives to Propel Continued Advancements in Cancer Drug Innovation

In synthesizing the core findings, the review underscores how immuno-oncology breakthroughs, precision medicine tools, and digital health integrations collectively redefine the cancer treatment paradigm. The cumulative effects of new trade policies highlight the necessity for resilient supply chains and innovative reimbursement strategies to preserve patient access and commercial viability.

Segmentation analyses clarify nuanced demand drivers across therapeutic classes, administration modes, and care settings, while regional insights reveal differentiated growth enablers shaped by regulatory and infrastructure variances. The competitive landscape analysis illustrates that collaborative alliances and agile portfolio management are essential for maintaining differentiation in a crowded pipeline.

Looking forward, the interplay between scientific innovation, regulatory evolution, and patient-centric frameworks promises to sustain momentum in oncology drug development. Stakeholders who embrace integrated research models, engage with payers on value-based approaches, and invest in resilient operational infrastructures will be best positioned to deliver transformative therapies and secure long-term market leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of CAR T-cell therapies into earlier lines of treatment for solid tumors
  • 5.2. Growth of tumor-agnostic therapies driven by biomarker-focused regulatory approvals
  • 5.3. Integration of AI-driven diagnostic platforms to optimize personalized cancer drug selection
  • 5.4. Rising investment in oral oncolytics for chronic management of advanced cancer patients
  • 5.5. Surge in combination regimens pairing immunotherapy with targeted small molecules
  • 5.6. Acceleration of precision oncology through liquid biopsy-guided treatment monitoring
  • 5.7. Emergence of next-generation antibody-drug conjugates with novel cytotoxic payloads
  • 5.8. Strategic partnerships between biotech and big pharma to fast-track oncology pipelines
  • 5.9. Regulatory incentives fueling development of rare cancer drugs under orphan drug pathways
  • 5.10. Adoption of real-world evidence to support post-market surveillance and label expansions

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cancer Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Chemotherapy
    • 8.2.1. Alkylating Agents
    • 8.2.2. Antimetabolites
    • 8.2.3. Antitumor Antibiotics
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
    • 8.5.1. Apoptosis-inducing Drugs
    • 8.5.2. Monoclonal Antibodies
    • 8.5.3. Tyrosine Kinase Inhibitors (TKIs)

9. Cancer Drugs Market, by Administration Route

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intravenous
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Cancer Drugs Market, by Therapy Type

  • 10.1. Introduction
  • 10.2. Combination Therapy
  • 10.3. Monotherapy

11. Cancer Drugs Market, by Cancer Type

  • 11.1. Introduction
  • 11.2. Breast Cancer
  • 11.3. Colorectal Cancer
  • 11.4. Liver Cancer
  • 11.5. Lung Cancer
  • 11.6. Pancreatic Cancer
  • 11.7. Prostate Cancer

12. Cancer Drugs Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Home Healthcare
  • 12.4. Hospitals & Clinics

13. Cancer Drugs Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Retail Pharmacy

14. Americas Cancer Drugs Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Cancer Drugs Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Cancer Drugs Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Amgen Inc.
    • 17.3.3. Astellas Pharma Inc
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Bayer AG
    • 17.3.6. BeiGene, Ltd.
    • 17.3.7. Bristol-Myers Squibb Company
    • 17.3.8. Daiichi Sankyo Company, Limited
    • 17.3.9. Dr. Reddy's Laboratories Ltd.
    • 17.3.10. Eli Lilly and Company
    • 17.3.11. F. Hoffmann-La Roche Ltd
    • 17.3.12. Fresenius Kabi AG
    • 17.3.13. Getwell Oncology Pvt Ltd
    • 17.3.14. GlaxoSmithKline plc
    • 17.3.15. Incyte Corporation
    • 17.3.16. Kite Pharma, Inc by Gilead Company
    • 17.3.17. Medivir AB
    • 17.3.18. Merck & Co., Inc.
    • 17.3.19. Nammi Therapeutics, Inc.
    • 17.3.20. Novartis AG
    • 17.3.21. Pfizer Inc.
    • 17.3.22. Sanofi S.A.
    • 17.3.23. Sun Pharmaceutical Industries Ltd.
    • 17.3.24. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
    • 17.3.25. Takeda Pharmaceutical Company Limited

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. CANCER DRUGS MARKET: RESEARCHAI
  • FIGURE 28. CANCER DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. CANCER DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 30. CANCER DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 213. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 217. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 233. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 235. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 236. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 245. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 249. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 251. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 252. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 253. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 261. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 265. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 267. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 268. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 269. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 271. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 275. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 277. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 283. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 284. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 285. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 330. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 341. DENMARK CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. DENMARK CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 343. DENMARK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 344. DENMARK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 345. DENMARK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 346. DENMARK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 347. DENMARK CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 348. DENMARK CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 349. DENMARK CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. DENMARK CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 351. DENMARK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. DENMARK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 353. DENMARK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. DENMARK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 355. DENMARK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 356. DENMARK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 357. NETHERLANDS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. NETHERLANDS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 359. NETHERLANDS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 360. NETHERLANDS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 361. NETHER